Festuccia W T, Laplante M, Berthiaume M, Gélinas Y, Deshaies Y
Laval Hospital Research Center, Faculty of Medicine, Laval University, Quebec, G1V 4G5, Canada.
Diabetologia. 2006 Oct;49(10):2427-36. doi: 10.1007/s00125-006-0336-y. Epub 2006 Aug 14.
AIMS/HYPOTHESIS: The aim of this study was to investigate the effect and mechanisms of action of in vivo peroxisome proliferator-activated receptor gamma (PPARgamma) activation on white adipose tissue (WAT) lipolysis and NEFA metabolism.
Study rats were treated for 7 days with 15 mg/kg of rosiglitazone per day; control rats were not treated. After a 6-h fast, lipolysis and levels of mRNA for lipases were assessed in explants from various adipose depots.
Rosiglitazone markedly increased basal and noradrenaline (norepinephrine)-stimulated glycerol and NEFA release from WAT explants, and amplified their inhibition by insulin. Primary adipocytes isolated from PPARgamma agonist-treated rats were also more responsive to noradrenaline stimulation expressed per cell, ruling out a contribution of an altered number of mature adipocytes in explants. Rosiglitazone concomitantly increased levels of mRNA transcripts for adipose triglyceride lipase (ATGL) and monoglyceride lipase (MGL) in subcutaneous and visceral WAT, and mRNA for hormone-sensitive lipase (HSL) in subcutaneous WAT. Lipase expression increased within 12 h of in vitro exposure of naïve explants to rosiglitazone, suggesting direct transcriptional activation. In parallel, chronic in vivo treatment with rosiglitazone lowered plasma NEFAs and in WAT its expected stimulatory action on glycerol and NEFA recycling, and on the expression of genes involved in NEFA uptake and retention by WAT, such processes counteracting net NEFA export.
CONCLUSIONS/INTERPRETATION: These findings demonstrate that, in the face of its plasma NEFA-lowering action, PPARgamma agonism stimulates WAT lipolysis, an effect that is compensated by lipid-retaining pathways. The results further suggest that PPARgamma agonism stimulates lipolysis by increasing the lipolytic potential, including the expression levels of the genes encoding adipose triglyceride lipase and monoglyceride lipase.
目的/假设:本研究旨在探讨体内过氧化物酶体增殖物激活受体γ(PPARγ)激活对白色脂肪组织(WAT)脂解作用及脂肪酸(NEFA)代谢的影响和作用机制。
研究用大鼠每天给予15mg/kg罗格列酮,持续治疗7天;对照大鼠不进行治疗。禁食6小时后,评估来自不同脂肪库的外植体中的脂解作用和脂肪酶的mRNA水平。
罗格列酮显著增加基础状态下以及去甲肾上腺素刺激的WAT外植体甘油和NEFA释放,并增强胰岛素对其释放的抑制作用。从经PPARγ激动剂处理的大鼠分离出的原代脂肪细胞,对去甲肾上腺素刺激的反应性也更高(以每个细胞计算),排除了外植体中成熟脂肪细胞数量改变的影响。罗格列酮同时增加皮下和内脏WAT中脂肪甘油三酯脂肪酶(ATGL)和甘油单酯脂肪酶(MGL)的mRNA转录水平,以及皮下WAT中激素敏感性脂肪酶(HSL)的mRNA水平。幼稚外植体在体外暴露于罗格列酮12小时内,脂肪酶表达增加,提示存在直接转录激活作用。同时,罗格列酮长期体内治疗降低血浆NEFAs水平,并且在WAT中,其对甘油和NEFA再循环以及对WAT中参与NEFA摄取和潴留的基因表达的预期刺激作用降低,这些过程抵消了NEFA的净输出。
结论/解读:这些发现表明,尽管PPARγ激动剂具有降低血浆NEFAs的作用,但它仍能刺激WAT脂解,这种作用可被脂质潴留途径所补偿。结果还提示,PPARγ激动剂通过增加脂解潜能,包括编码脂肪甘油三酯脂肪酶和甘油单酯脂肪酶的基因表达水平,来刺激脂解作用。